ADAMTS13 and von Willebrand factor assessment in steady state and acute vaso‐occlusive crisis of sickle cell disease
Abstract Background Sickle cell disease (SCD) is characterized by vaso‐occlusive crisis (VOC), acute chest syndrome (ACS) and multiorgan failure (MOF) complicated by thrombosis. Von Willebrand factor (VWF) is a strong marker of SCD‐related endothelial injury. Objectives To decipher the role of VWF a...
Main Authors: | , , , , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2021-01-01
|
Series: | Research and Practice in Thrombosis and Haemostasis |
Subjects: | |
Online Access: | https://doi.org/10.1002/rth2.12460 |
id |
doaj-7a6de7102e76435f88d5c97a5e44340a |
---|---|
record_format |
Article |
spelling |
doaj-7a6de7102e76435f88d5c97a5e44340a2021-02-24T09:15:39ZengWileyResearch and Practice in Thrombosis and Haemostasis2475-03792021-01-015119720310.1002/rth2.12460ADAMTS13 and von Willebrand factor assessment in steady state and acute vaso‐occlusive crisis of sickle cell diseaseJulien Demagny0Aurélie Driss1Alain Stepanian2Nadia Anguel3Louis Affo4Damien Roux5Anoosha Habibi6Sandrine Benghezal7Sophie Capdenat8Paul Coppo9Françoise Driss10Agnès Veyradier11Service d’Hématologie BiologiqueHôpital LariboisièreAP‐HP.NordUniversité de Paris Paris FranceService d’HémaphérèseHôpital de BicêtreAP‐HP.SudUniversité Paris Saclay Le Kremlin Bicêtre FranceService d’Hématologie BiologiqueHôpital LariboisièreAP‐HP.NordUniversité de Paris Paris FranceService de Réanimation Médicale Hôpital de BicêtreAP‐HP.SudUniversité Paris Saclay Le Kremlin Bicêtre FranceService de Médecine Interne Hôpital Louis MourierAP‐HP.NordUniversité de Paris Paris FranceService de Réanimation Médico‐Chirurgicale Hôpital Louis MourierAP‐HP.NordUniversité de Paris Paris FranceUnité des maladies du globule rougeHôpital Henri MondorAP‐HPUniversité Paris Est Créteil‐Val de marne Paris FranceService d’Hématologie BiologiqueHôpital LariboisièreAP‐HP.NordUniversité de Paris Paris FranceService d’Hématologie BiologiqueHôpital LariboisièreAP‐HP.NordUniversité de Paris Paris FranceCentre National de Référence des Microangiopathies Thrombotiques (CNR‐MAT) Département D’hématologie clinique Hôpital Saint AntoineAPHP.SUUniversité Pierre et Marie Curie Paris FranceService d’HémaphérèseHôpital de BicêtreAP‐HP.SudUniversité Paris Saclay Le Kremlin Bicêtre FranceService d’Hématologie BiologiqueHôpital LariboisièreAP‐HP.NordUniversité de Paris Paris FranceAbstract Background Sickle cell disease (SCD) is characterized by vaso‐occlusive crisis (VOC), acute chest syndrome (ACS) and multiorgan failure (MOF) complicated by thrombosis. Von Willebrand factor (VWF) is a strong marker of SCD‐related endothelial injury. Objectives To decipher the role of VWF and its specific‐cleaving metalloprotease, ADAMTS13, in the vaso‐occlusive and thrombotic process of SCD. Patients/Methods We investigated the VWF antigen (Ag), ADAMTS13 activity, ADAMTS13 Ag and ADAMTS13 IgGs in a cohort of 65 patients with SCD prospectively enrolled in a 20‐month period from three centers. Patients were divided into two groups: an asymptomatic group (n = 30) with treated or untreated SCD at steady state, and a VOC/ACS group (n = 35) with SCD with VOC/ACS requiring either medical management or intensive care management for MOF. Results and Conclusions VWF:Ag levels were increased (median, 167 IU/dL; interquartile range [IQR], 124 ‐ 279), especially in patients with VOC SCD (227 IU/dL; IQR, 134‐305; P = .04), and positively correlated with inflammatory markers (P < .02). Median ADAMTS13 activity was normal (70 IU/dL; IQR, 60‐80), but 7 patients exhibited a partial deficiency between 25 and 45 IU/dL. ADAMTS13 activity/VWF:Ag ratio, however, did not change during VOC. Median ADAMTS13:Ag was slightly decreased (611 ng/mL; IQR, 504‐703) with no significant difference between groups. Surprisingly, ADAMTS13 IgGs were detected in 33 (51%) of our patients. We conclude that, in SCD, VWF:Ag and nonrelevant ADAMTS13 IgGs may reflect the severity of the inflammatory vasculopathy enhancing vaso‐occlusive and thrombotic complications.https://doi.org/10.1002/rth2.12460ADAMTS13sickle cell diseasethrombosisvaso‐occlusionvon Willebrand factor |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Julien Demagny Aurélie Driss Alain Stepanian Nadia Anguel Louis Affo Damien Roux Anoosha Habibi Sandrine Benghezal Sophie Capdenat Paul Coppo Françoise Driss Agnès Veyradier |
spellingShingle |
Julien Demagny Aurélie Driss Alain Stepanian Nadia Anguel Louis Affo Damien Roux Anoosha Habibi Sandrine Benghezal Sophie Capdenat Paul Coppo Françoise Driss Agnès Veyradier ADAMTS13 and von Willebrand factor assessment in steady state and acute vaso‐occlusive crisis of sickle cell disease Research and Practice in Thrombosis and Haemostasis ADAMTS13 sickle cell disease thrombosis vaso‐occlusion von Willebrand factor |
author_facet |
Julien Demagny Aurélie Driss Alain Stepanian Nadia Anguel Louis Affo Damien Roux Anoosha Habibi Sandrine Benghezal Sophie Capdenat Paul Coppo Françoise Driss Agnès Veyradier |
author_sort |
Julien Demagny |
title |
ADAMTS13 and von Willebrand factor assessment in steady state and acute vaso‐occlusive crisis of sickle cell disease |
title_short |
ADAMTS13 and von Willebrand factor assessment in steady state and acute vaso‐occlusive crisis of sickle cell disease |
title_full |
ADAMTS13 and von Willebrand factor assessment in steady state and acute vaso‐occlusive crisis of sickle cell disease |
title_fullStr |
ADAMTS13 and von Willebrand factor assessment in steady state and acute vaso‐occlusive crisis of sickle cell disease |
title_full_unstemmed |
ADAMTS13 and von Willebrand factor assessment in steady state and acute vaso‐occlusive crisis of sickle cell disease |
title_sort |
adamts13 and von willebrand factor assessment in steady state and acute vaso‐occlusive crisis of sickle cell disease |
publisher |
Wiley |
series |
Research and Practice in Thrombosis and Haemostasis |
issn |
2475-0379 |
publishDate |
2021-01-01 |
description |
Abstract Background Sickle cell disease (SCD) is characterized by vaso‐occlusive crisis (VOC), acute chest syndrome (ACS) and multiorgan failure (MOF) complicated by thrombosis. Von Willebrand factor (VWF) is a strong marker of SCD‐related endothelial injury. Objectives To decipher the role of VWF and its specific‐cleaving metalloprotease, ADAMTS13, in the vaso‐occlusive and thrombotic process of SCD. Patients/Methods We investigated the VWF antigen (Ag), ADAMTS13 activity, ADAMTS13 Ag and ADAMTS13 IgGs in a cohort of 65 patients with SCD prospectively enrolled in a 20‐month period from three centers. Patients were divided into two groups: an asymptomatic group (n = 30) with treated or untreated SCD at steady state, and a VOC/ACS group (n = 35) with SCD with VOC/ACS requiring either medical management or intensive care management for MOF. Results and Conclusions VWF:Ag levels were increased (median, 167 IU/dL; interquartile range [IQR], 124 ‐ 279), especially in patients with VOC SCD (227 IU/dL; IQR, 134‐305; P = .04), and positively correlated with inflammatory markers (P < .02). Median ADAMTS13 activity was normal (70 IU/dL; IQR, 60‐80), but 7 patients exhibited a partial deficiency between 25 and 45 IU/dL. ADAMTS13 activity/VWF:Ag ratio, however, did not change during VOC. Median ADAMTS13:Ag was slightly decreased (611 ng/mL; IQR, 504‐703) with no significant difference between groups. Surprisingly, ADAMTS13 IgGs were detected in 33 (51%) of our patients. We conclude that, in SCD, VWF:Ag and nonrelevant ADAMTS13 IgGs may reflect the severity of the inflammatory vasculopathy enhancing vaso‐occlusive and thrombotic complications. |
topic |
ADAMTS13 sickle cell disease thrombosis vaso‐occlusion von Willebrand factor |
url |
https://doi.org/10.1002/rth2.12460 |
work_keys_str_mv |
AT juliendemagny adamts13andvonwillebrandfactorassessmentinsteadystateandacutevasoocclusivecrisisofsicklecelldisease AT aureliedriss adamts13andvonwillebrandfactorassessmentinsteadystateandacutevasoocclusivecrisisofsicklecelldisease AT alainstepanian adamts13andvonwillebrandfactorassessmentinsteadystateandacutevasoocclusivecrisisofsicklecelldisease AT nadiaanguel adamts13andvonwillebrandfactorassessmentinsteadystateandacutevasoocclusivecrisisofsicklecelldisease AT louisaffo adamts13andvonwillebrandfactorassessmentinsteadystateandacutevasoocclusivecrisisofsicklecelldisease AT damienroux adamts13andvonwillebrandfactorassessmentinsteadystateandacutevasoocclusivecrisisofsicklecelldisease AT anooshahabibi adamts13andvonwillebrandfactorassessmentinsteadystateandacutevasoocclusivecrisisofsicklecelldisease AT sandrinebenghezal adamts13andvonwillebrandfactorassessmentinsteadystateandacutevasoocclusivecrisisofsicklecelldisease AT sophiecapdenat adamts13andvonwillebrandfactorassessmentinsteadystateandacutevasoocclusivecrisisofsicklecelldisease AT paulcoppo adamts13andvonwillebrandfactorassessmentinsteadystateandacutevasoocclusivecrisisofsicklecelldisease AT francoisedriss adamts13andvonwillebrandfactorassessmentinsteadystateandacutevasoocclusivecrisisofsicklecelldisease AT agnesveyradier adamts13andvonwillebrandfactorassessmentinsteadystateandacutevasoocclusivecrisisofsicklecelldisease |
_version_ |
1724253099372052480 |